Skip to content

US · BHC · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Bausch Health Companies Inc. (BHC) intrinsic value and stock valuation

$8.22as of 2026-11-21 · Mkt cap 2.35B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Bausch Health Companies Inc. DCF and intrinsic value

InvestorsCraft values BHC with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from BHC’s statements →

Bausch Health Companies Inc. Graham Number

Graham Number: $3.11d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Laval, QC H7L 4A8 bauschhealth.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$10.3B+5% 5y CAGRd
20112025
Net income
$157M
20112025
Free cash flow
$1B+4.6% 5y CAGRd
20112025
Total equity
$376.3M-9.1% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$10.3B$9.63B$8.76B$8.12B$8.43B
Operating income$2.19B$1.55B$963M$454M$450M
Net income$157M-$-46M-$-592M-$-225M-$-948M
EPSd$418.7K-$-125K-$-1.62M-$-621.55K-$-2.64M
Operating cash flow$1.4B$1.6B$1.03B-$-728M$1.43B
Capital expenditure-$-397M-$-337M-$-272M-$-268M-$-283M
Free cash flow$1B$1.26B$760M-$-996M$1.14B
Total assets$26.3B$26.5B$27.4B$25.7B$29.2B
Total debt$21.2B$21.8B$22.4B$20.8B$22.7B
Net debt$19.9B$20.6B$21.4B$20.2B$22.1B
Total equity$376.3M-$-322M-$-82M$260M-$-34M
Cash and short-term investments$1.32B$1.18B$947M$564M$582M
Income statement
20252024202320222021
Revenue$10.3B$9.63B$8.76B$8.12B$8.43B
Cost of revenue$3.01B$2.78B$2.56B$2.36B$2.39B
Gross profit$7.25B$6.84B$6.2B$5.76B$6.04B
Research and development expenses$629M$634M$604M$530M$473M
Selling, general and administrative expenses$3.44B$3.28B$2.9B$2.53B$2.49B
Other expenses$1B$1.38B$1.74B$2.25B$2.63B
Operating expenses$5.07B$5.3B$5.24B$5.31B$5.59B
Cost and expenses$8.08B$8.08B$7.79B$7.67B$7.98B
Interest income$48M$33M$26M$14M$7M
Interest expense$1.6B$1.39B$1.33B$1.46B$1.43B
Depreciation and amortization$1.21B$1.27B$1.26B$1.39B$1.55B
Ebitda$3.18B$3.13B$2.89B$2.88B$3.26B
Operating income$2.19B$1.55B$963M$454M$450M
Total other income/expenses, net-$-1.82B-$-1.38B-$-1.35B-$-583M-$-1.47B
Income before tax$367M$167M-$-390M-$-129M-$-1.02B
Income tax expense$247M$239M$221M$83M-$-87M
Net income$157M-$-46M-$-592M-$-225M-$-948M
Weighted average shares outstanding$370.9M$368M$365.4M$362M$358.9M
Weighted average diluted shares outstanding$375M$368M$364.9M$362M$358.9M
Balance sheet
20252024202320222021
Cash and short-term investments$1.32B$1.18B$947M$564M$582M
Net receivables$2.35B$2.14B$2B$1.79B$1.78B
Inventory$1.63B$1.6B$1.54B$1.09B$993M
Total current assets$6.15B$5.77B$5.6B$4.25B$5.61B
Property, plant and equipment, net$2.07B$1.78B$1.71B$1.6B$1.6B
Goodwill and intangible assets$15.9B$16.6B$17.6B$17.3B$19.4B
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$20.2B$20.7B$21.8B$21.4B$23.6B
Total assets$26.3B$26.5B$27.4B$25.7B$29.2B
Accounts payable$598.9M$656M$719M$521M$407M
Short-term debt$296.5M$2.73B$450M$432M$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$4.17B$6.75B$4.3B$3.94B$5.2B
Long-term debt$20.9B$19.1B$21.9B$20.3B$22.7B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$21.8B$20.1B$23.1B$21.5B$24B
Capital lease obligations$189.7M$223M$0.00$0.00$0.00
Total liabilities$25.9B$26.8B$27.4B$25.4B$29.2B
Common stock$10.5B$10.5B$10.4B$10.4B$10.3B
Retained earnings-$-9.65B-$-9.82B-$-9.78B-$-9.19B-$-8.96B
Accumulated other comprehensive income (loss)-$-1.76B-$-2.18B-$-1.88B-$-2.06B-$-1.92B
Total equity$376.3M-$-322M-$-82M$260M-$-34M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$21.2B$21.8B$22.4B$20.8B$22.7B
Net debt$19.9B$20.6B$21.4B$20.2B$22.1B
Cash flow statement
20252024202320222021
Net income$120M-$-72M-$-611M-$-212M-$-937M
Depreciation and amortization$1.21B$1.27B$1.26B$1.39B$1.55B
Stock-based compensation$216M$150M$132M$126M$128M
Change in working capital-$-222.83M$7M-$-582M-$-396M-$-128M
Accounts receivable-$-136.35M-$-216M-$-195M-$-57M-$-229M
Inventory-$-12.21M-$-267M-$-322M-$-198M-$-16M
Accounts payable-$-77.33M$357M$158M-$-75M$121M
Net cash provided by operating activities$1.4B$1.6B$1.03B-$-728M$1.43B
Investments in property, plant and equipment-$-397M-$-337M-$-215M-$-218M-$-269M
Acquisitions, net$0.00$0.00-$-1.89B-$-45M$0.00
Net cash used for investing activities-$-595M-$-454M-$-2.15B-$-303M$409M
Common stock issued$0.00$0.00$0.00$675M$0.00
Common stock repurchased$0.00-$-26M$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-742M-$-868M$1.48B-$-474M-$-1.51B
Net change in cash$124M$239M$371M-$-1.53B$303M
Cash at end of period$1.33B$1.2B$962M$591M$2.12B
Operating cash flow$1.4B$1.6B$1.03B-$-728M$1.43B
Capital expenditure-$-397M-$-337M-$-272M-$-268M-$-283M
Free cash flow$1B$1.26B$760M-$-996M$1.14B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Bausch Health Companies Inc.

        Bausch Health Companies Inc., together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devices, and over-the-counter remedies. Its primary therapeutic focus areas include ophthalmology, digestive health, and dermatology. The enterprise conducts its operations through five principal divisions: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment is dedicated to vision care, encompassing surgical instruments, consumer eye health products, and ophthalmic pharmaceuticals. Salix specializes in delivering gastroenterology-specific products exclusively within the United States. The International Rx division markets Solta products, a range of branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across diverse geographies including Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. Ortho Dermatologics focuses on dermatological products in the U.S., in addition to distributing Solta's medical aesthetic devices globally. Finally, the Diversified Products segment supplies pharmaceutical solutions for neurology and other therapeutic categories, as well as generic medications and dental products, all within the U.S. The company was formerly known as Valeant Pharmaceuticals International, Inc., officially changing its name to Bausch Health Companies Inc. in July 2018. Its corporate headquarters are located in Laval, Canada.

        CEO
        Thomas J. Appio
        Employees
        20.3K
        Beta
        0.42

        Explore

        Frequently asked questions

        What is the intrinsic value of Bausch Health Companies Inc. (BHC)?

        Bausch Health Companies Inc. (BHC) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is BHC undervalued?

        BHC trades at a price of $8.22 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.